Chemomab is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently testing CM-101 in three phase 2 studies focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc)